Positive results for olaparib in men with metastatic prostate cancer

21 Apr 2015

Men with metastatic, castration-resistant prostate cancer that had mutations in genes linked to repair of damaged DNA were significantly more likely to respond to treatment with olaparib compared with patients who had disease without these mutations, according to data from the first stage of the phase II TOPARP clinical trial .

“TOPARP is an investigator-initiated clinical trial designed to test the anticancer effect of the PARP [poly ADP-ribose polymerase] inhibitor olaparib in men with metastatic, castration- resistant prostate cancer and, at the same time, to identify biomarkers predictive of response to olaparib,” said Joaquin Mateo, MD, a clinical research fellow in the Prostate Targeted Therapy Group and Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in the United Kingdom.

Design and results of the clinical trials

Mateo and colleagues enrolled 50 men with metastatic, castration-resistant prostate cancer in TOPARP-A trial. “For TOPARP-B, we are enrolling only patients who screen positive for the DNA repair mutations linked to response in TOPARP-A.”

Among the 49 patients for whom there were evaluable data, 16 had a response to olaparib treatment:

  • 6 patients had radiological responses, as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) guidelines and
  • 11 patients had biochemical responses, as assessed by a greater than 50 percent decrease in prostate-specific antigen (PSA) levels
  • 4 of these responses lasted more than one year

CareAcross-ampoules

Next-generation sequencing detected mutations in genes associated with DNA repair in tumor samples from 15 of the 49 patients evaluated. Of these patients, 13 had a response to olaparib.

The researchers calculated the specificity of the DNA repair gene panel to be 94%.

Durable anti-tumor activity

According to Mateo, this means that 94% of patients without these mutations will be correctly identified as not having the mutations and this will help clinicians select the right treatment for a patient because they can be reasonably certain that olaparib will not benefit a patient testing negative for the mutations.

“The data from TOPARP-A show that single-agent PARP inhibition with olaparib has durable anti-tumor activity in men with metastatic, castration-resistant prostate cancer and identify a molecularly distinct subgroup of patients that respond to the drug,” commented Mateo adding that these are potentially the first clinical data supporting molecular stratification of treatment in prostate cancer.

Source: eCancer News
No Comment